Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12533279 | 1.00 | KMT2A (0.51) | KMT2AMEN1NPSR1ALDH1A1POLB | |
| SCHEMBL1766751 | 1.00 | KMT2A (0.51) | KMT2AMEN1NPSR1ALDH1A1POLB | |
| SCHEMBL23961047 | 1.00 | KMT2A (0.51) | KMT2AMEN1NPSR1ALDH1A1POLB | |
| SCHEMBL23959329 | 0.98 | KMT2A (0.54) | KMT2AMEN1NPSR1ALDH1A1POLB | |
| SCHEMBL23961091 | 0.98 | KMT2A (0.54) | KMT2AMEN1NPSR1ALDH1A1POLB | |
| SCHEMBL23961118 | 0.83 | TSHR (0.53) | KMT2AMEN1NPSR1ALDH1A1POLB | |
| SCHEMBL25566925 | 0.83 | TSHR (0.53) | KMT2AMEN1NPSR1ALDH1A1POLB | |
| SCHEMBL30261137 | 0.81 | ALDH1A1 (0.59) | KMT2AMEN1ALDH1A1POLBTDP1 | |
| SCHEMBL26376274 | 0.79 | CD274 (0.41) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL23716892 | 0.77 | KMT2A (0.48) | KMT2AMEN1ALDH1A1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130438-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-02 | — | — | US | disclosed |
| US-7939569-B1 | Aniline analogs as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130438-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, PYGL, GYS1 | KMT2A 2610/4885MEN1 3530/4885NPSR1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.